You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
1 July 2024
Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
28 June 2024
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
13 June 2024
Formycon reports on the results of the Annual General Meeting
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
15 May 2024
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
8 May 2024
Formycon reports on successful operating business and financial figures for the first quarter of 2024
7 May 2024
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
2 May 2024
Formycon hosts conference call on the results of the first quarter 2024
29 April 2024
Formycon AG: Dr. Marc Mikulcik, buy
25 April 2024
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
24 April 2024
Formycon AG: Dr. Stefan Glombitza, buy
22 April 2024
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
12 April 2024
Convincing overall performance – Formycon reports preliminary results for the financial year 2023 and exceeds forecast
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
11 April 2024
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
18 March 2024
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
11 March 2024
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
29 January 2024
Gedeon Richter becomes strategic investor of Formycon via equity investment
Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
18 January 2024
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
4 January 2024
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
27 December 2023
Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
7 December 2023
Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®
5 December 2023
Formycon announces participation in international Investor Conferences in Q1/2024
30 November 2023
Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration
27 November 2023
Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
13 November 2023
Formycon publishes nine-month results for 2023
10 November 2023
Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
10 October 2023
Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
29 September 2023
Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
Aug
2024
Publication half-yearly financial statements
25
Nov 24
Analysts’ Conference
Nov
Press Release – quarterly statement (call-date Q3)